Dr. David I. Levenson, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,506
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: New York University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
FL license ME59003 -
Specialist
FL license ME59003
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Boca Raton Regional Hospital Boca Raton, FL
- Bethesda Hospital East Boynton Beach, FL
- Delray Medical Center Delray Beach, FL
Medical groups
- New York University (6,134 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,506
- Services billed
- 19,296
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Blood glucose (sugar) test performed by hand-held instrument | 2,335 | 1,163 |
| Established patient office or other outpatient visit, 30-39 minutes | 2,217 | 1,206 |
| Insertion of needle into vein for collection of blood sample | 2,082 | 977 |
| Hemoglobin a1c level | 1,497 | 897 |
| Blood test, basic group of blood chemicals (calcium, total) | 1,243 | 777 |
| Blood test, thyroid stimulating hormone (tsh) | 1,186 | 788 |
| Thyroxine (thyroid chemical), free | 1,180 | 788 |
| Ldl cholesterol level | 974 | 746 |
| Blood test, lipids (cholesterol and triglycerides) | 973 | 746 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 494 | 252 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Boca Raton, FL | 1,627 |
| Rosuvastatin Calcium Other prescribers in Boca Raton, FL | 624 |
| Synthroid (levothyroxine sodium) Other prescribers in Boca Raton, FL | 563 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Boca Raton, FL | 528 |
| Atorvastatin Calcium Other prescribers in Boca Raton, FL | 512 |
| Ozempic (semaglutide) Other prescribers in Boca Raton, FL | 352 |
| Metformin Hcl Other prescribers in Boca Raton, FL | 289 |
| Nateglinide | 272 |
| Mounjaro (tirzepatide) Other prescribers in Boca Raton, FL | 268 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in Boca Raton, FL | 258 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 33 payments worth $1,002 in total to this clinician.
| Medicure Pharma Inc. | $195 |
|---|---|
| Genzyme Corporation | $125 |
| Amgen Inc. | $118 |
| Corcept Therapeutics | $95.64 |
| Dexcom, Inc. | $76.26 |
| Bayer HealthCare Pharmaceuticals Inc. | $67.14 |
| Recordati_rare_diseases_inc. | $60.98 |
| Neurocrine Biosciences, Inc. | $50.19 |
| Food and Beverage | $978 |
|---|---|
| Education | $24.04 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Neurocrine Biosciences, Inc. Mar 14, 2025 | Education CRENESSITY · Neuropsychiatry · in-kind | $24.04 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $9,826 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Novo Nordisk As
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.